ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CADX (MM)

14.00
0.00 (0.00%)
20 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
(MM) NASDAQ:CADX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 14.00 0 01:00:00

SHAREHOLDER DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Cadence Pharmaceuticals, Inc. in Connecti...

17/02/2014 6:54pm

Business Wire


(MM) (NASDAQ:CADX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more (MM) Charts.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc. (“Cadence” or the “Company”) (Nasdaq: CADX) relating to the acquisition by Mallinckrodt plc (“MNK”).

Click here to learn more about the investigation http://brodsky-smith.com/721-cadx-cadence-pharmaceuticals-inc-.html, or call: 877-534-2590. There is no cost or obligation to you.

Cadence announced that the transaction is a Tender Offer, which should close, unless extended, 20 days after commencement. Under the terms of the transaction, Cadence shareholders will receive only $14.00 in cash for each share of Cadence stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Cadence for not acting in the Company’s shareholders' best interests in connection with the sale process.

The transaction may undervalue the Company as it is below the premium paid in comparable transactions and an analyst has set a $15.00 per share price target on Cadence stock. In addition, the Company has announced OFIRMEV has continued to gain market share and posted year-over-year sales growth of more than 100% in each quarter of 2013.

If you own shares of Cadence common stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com, or by visiting http://brodsky-smith.com/721-cadx-cadence-pharmaceuticals-inc-.html, or calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and case action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

Brodsky & Smith, LLCJason L. Brodsky, EsquireEvan J. Smith, Esquire877-LEGAL-90investorrelations@brodsky-smith.comhttp://brodsky-smith.com/721-cadx-cadence-pharmaceuticals-inc-.html

1 Year (MM) Chart

1 Year (MM) Chart

1 Month (MM) Chart

1 Month (MM) Chart

Your Recent History

Delayed Upgrade Clock